Tumor-associated NK Cells Regulate Distinct CD8+ T-cell Differentiation Program in Cancer and Contribute to Resistance against Immune Checkpoint Blockers
No‐Joon Song(The Ohio State University), Zihai Li(MUSC Hollings Cancer Center), Bethany L. Mundy-Bosse(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jean‐Christophe Marine(Vlaams Instituut voor Biotechnologie), Kyeong Joo Jung(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Parker Kronen(The Ohio State University), Yi Wang(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Qin Ma(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jayajit Das(Nationwide Children's Hospital), Niccolò Roda(VIB-KU Leuven Center for Cancer Biology), Hyeongseon Jeon(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Juan Xie(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Joanna Poźniak(VIB-KU Leuven Center for Cancer Biology), Nigel Cox(Nationwide Children's Hospital), Anjun Ma(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Nicholas Denko(The Ohio State University), Anqi Li(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), David P. Carbone(The Ohio State University), William E. Carson(Comprehensive Blood & Cancer Center), Brian Riesenberg(Medical University of South Carolina), Darren Wethington(Nationwide Children's Hospital), Dongjun Chung(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Kelsi Reynolds(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Tong Xiao(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Christin E. Burd(The Ohio State University)
Cited by 17
Related Papers
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2015|1.2k
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis
|Cancer Cell|2004|1.1k
Non-small-cell lung cancer
|Nature Reviews Disease Primers|2015|1.1k
Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis
|Cancer Cell|2008|917
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|661